Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 22 January 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Antiviral therapy for Hep B-health workers reduces work restrictions

Antiviral therapy for Hep B-infected health care workers prevents work restriction without jeopardizing patient safety, finds the latest Journal of Viral Hepatitis.

News image

fiogf49gjkf04

Highly viremic health care workers are often advised to restrict performing exposure prone procedures.

This is to prevent transmission of Hepatitis B virus from health care workers to patients.

Dr Janssen and colleagues from the Netherlands offered highly viremic health care workers antiviral therapy.

The therapy was offered to prevent loss of highly qualified medical personnel, and simultaneously minimize transmission risk to patients.

The research team then evaluated the effects of this strategy.

The team monitored 18 Hepatitis B-infected health care workers every 3 to 6 months for a median period of 6 years.

Antiviral therapy persistently suppresses virus levels below 105 copies/mL
Journal of Viral Hepatitis

Antiviral therapy was offered if Hepatitis B viral DNA was above 105 copies/mL.

The researchers also offered antiviral therapy if exposure prone procedures were performed or active liver disease was present.

Median Hepatitis B virus DNA levels during antiviral therapy were analyzed.

The team also measured the percentage of days with Hepatitis B virus DNA above 103, 104 and 105 copies/mL.

Reduction of Hepatitis B virus DNA during antiviral treatment was measured.

The team evaluated these outcomes in Hepatitis B e antigen-positive and Hepatitis B e antigen-negative health care workers separately.

The researchers achieved prolonged viral suppression in both Hepatitis B e antigen-positive, as well as Hepatitis B e antigen-negative health care workers.

In Hepatitis B e antigen-negative health care workers, treatment with interferon or lamivudine maintained virus DNA levels below 105 copies/mL.

For Hepatitis B e antigen-positive health care workers continuous treatment with tenofovir or entecavir was essential for reaching low viremia persistently.

In 2004, the team observed that median Hepatitis B virus DNA levels in both Hepatitis B e antigen-negative and -positive workers were below 103 copies/mL.

The researchers noted that all health care workers executed their professional work full-range.

Dr Janssen's team concludes, “For both Hepatitis B e antigen-positive and Hepatitis B e antigen-negative health care workers, antiviral treatment is effective in persistent suppression of virus levels below 105 copies/mL.”

“This observation supports antiviral therapy as a viable management option instead of work restriction.”

“Regular expert monitoring including quantification of Hepatitis B virus DNA has to be provided.”

J Vir Hep 2007: 14(5): 350
17 April 2007

Go to top of page Email this page Email this page to a colleague

 22 January 2018 
Costs of biologic therapies for IBD in the USA
 22 January 2018 
Western vs Asian guidelines for colon cancer management
 22 January 2018 
Improving symptoms in GERD
 19 January 2018 
Ileoanal pouch microbiota
 19 January 2018 
Predicting the risk of early surgery in Crohn’s
 19 January 2018 
Lifestyle intervention vs gastric bypass for obesity and diabetes
 18 January 2018 
Healthcare costs of liver cancer in the USA
 18 January 2018 
High-risk adenomas at colonoscopy
 18 January 2018 
Sleeve gastrectomy vs Roux-en-Y gastric bypass
 17 January 2018 
“Weekend effect” in upper GI hemorrhage
 17 January 2018 
Gut dysbiosis and non-antibiotic prescription medications
 17 January 2018 
Reducing surgical infections in high-outlier colorectal unit
 16 January 2018 
Bundle of care in GI cancer surgery
 16 January 2018 
Anxiety about colonoscopy
 16 January 2018 
Thiopurines and colorectal neoplasia in IBD
 15 January 2018 
Risks of death after liver transplants for liver cancer
 15 January 2018 
Recent advances in hepatocellular carcinoma
 15 January 2018 
Ileostomy output using telemedicine
 12 January 2018 
Surveillance protocols after colorectal cancer resection
 12 January 2018 
Biologic therapy by pregnant women with IBD and infant vaccines
 12 January 2018 
Biologic therapies for IBD in the USA
 11 January 2018 
Genetic risk factors in GERD
 11 January 2018 
Predictor of colorectal adenoma
 11 January 2018 
Ectopic pregnancy in IBD 
 10 January 2018 
Fecal immunochemical tests for colorectal cancer screening
 10 January 2018 
Risk factors for advanced NAFLD
 10 January 2018 
Dyspepsia prevalence with gastroesophageal reflux–type symptoms
 09 January 2018 
Screening intervals for people with family histories of colorectal cancer
 09 January 2018 
Financial impact of colorectal cancer
 09 January 2018 
Current practice and future research in autoimmune hepatitis
 08 January 2018 
Reliability of the IBD index
 08 January 2018 
Improving prognosis in patients with primary sclerosing cholangitis
 08 January 2018 
Aprepitant and nausea with gastroparesis
 05 January 2018 
Autoimmune pancreatitis and IBD
 05 January 2018 
Primary nonresponse to infliximab therapy
 05 January 2018 
Anesthesia assistance in outpatient colonoscopy
 04 January 2018 
Dietary polyphenols in the etiology of IBD
 04 January 2018 
Local esophageal food allergen injections in eosinophilic esophagitis
 04 January 2018 
Yoga vs low-FODMAP in IBS
 03 January 2018 
Population health management for IBD
 03 January 2018 
GERD in asthma and COPD
 03 January 2018 
Critical research gaps in colorectal cancer
 22 December 2017 
Costs of extrahepatic manifestations of Hep C
 22 December 2017 
Cholera vaccine and risk of death in colorectal cancer
 22 December 2017 
Colonoscopy after colorectal cancer resection
 21 December 2017 
Human oral microbiome and pancreatic cancer risk
 21 December 2017 
Health management for IBD
 21 December 2017 
PPI and Alzheimer's disease
 20 December 2017 
Management of abnormal liver blood tests
 20 December 2017 
Incidence of biopsy-verified celiac disease
 20 December 2017 
Osteoporotic fractures in Barrett's esophagus
 19 December 2017 
Alcohol abstinence and alcoholic hepatitis
 19 December 2017 
Family burden of pediatric Crohn's in the USA
 19 December 2017 
Early readmission in IBD patients
 18 December 2017 
Colorectal cancer mortality with low-risk adenomas at colonoscopy
 18 December 2017 
Disease activity indices in celiac disease
 18 December 2017 
Smoking behaviour predicted the risk of surgery in Crohn's
 15 December 2017 
Molecular classification of Crohn's disease
 15 December 2017 
Medical cannabinoid legalization policy and vomiting
 15 December 2017 
Inflammatory diet pattern and colorectal cancer risk

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us